Owkin joins the Gaia-X European Association to contribute to a sustainable European data ecosystem
Owkin has joined the Gaia-X European Association for Data and Cloud AISBL, a European project bringing together representatives from business, politics, policy, technology and research from across Europe and beyond to build a federated and secure data infrastructure.
The Gaia-X community, which has 350 members, collaborates to develop a data infrastructure that adheres to a common standard – the Gaia-X standard. The project aims to facilitate openness, transparency, and sovereignty in data sharing.
Gaia-X draws on the broadest range of expertise to co-create the future of European digital infrastructure across dedicated data spaces supporting the most critical industries.
This collaboration will foster the development of the Gaia-X's federated data infrastructure and strengthen ties between Owkin and experts in the life sciences and healthcare communities, helping to further innovate in medicine to improve the health sector and associated services.
Learn more about the Gaia-X Association, including its principal objectives, organizational structure, deliverables, and architectural framework.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.